Citi Sticks to Their Buy Rating for Royalty Pharma (RPRX)
In a report released on January 5, Geoff Meacham from Citi reiterated a Buy rating on Royalty Pharma, with a price target of $48.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Meacham is a 4-star analyst with an average return of 7.5% and a 55.25% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Bristol-Myers Squibb, and Gilead Sciences.
In a report released on December 25, TipRanks – OpenAI also reiterated a Buy rating on the stock with a $45.00 price target.
Based on Royalty Pharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $609.29 million and a net profit of $288.22 million. In comparison, last year the company earned a revenue of $564.69 million and had a net profit of $543.99 million
Read More on RPRX:
Disclaimer & DisclosureReport an Issue
- Royalty Pharma acquires reaming royalty interest in Evrysdi for $240M upfront
- Royalty Pharma Announces Planned Legal Leadership Transition
- Royalty Pharma Gains From FDA Approval of MYQORZO
- Royalty Pharma acquires royalty interest in Nuvalent’s neladalkib, zidesamtinib
- Royalty Pharma price target raised to $45 from $42 at TD Cowen
